Pulsed-dye Laser Treatment Prior to Surgical Excision
| Status: | Not yet recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/2/2016 |
| Start Date: | June 2015 |
| End Date: | July 2016 |
| Contact: | Kachiu Lee, MD |
| Email: | klee52@mgh.harvard.edu |
| Phone: | 617-371-4711 |
This prospective pilot study will investigate whether use of a pulsed dye laser (PDL) prior
to surgical excision can improve the appearance and symptoms of scars. The primary outcome
measurement for the study is the quality of the scar in areas pre-treated with PDL vs.
control (cryogen spray only). For this study, subjects who are scheduled for a dermatologic
surgical excision will have half of the surgical area pre-treated with PDL and the other
half pre-treated with cryogen spray.
to surgical excision can improve the appearance and symptoms of scars. The primary outcome
measurement for the study is the quality of the scar in areas pre-treated with PDL vs.
control (cryogen spray only). For this study, subjects who are scheduled for a dermatologic
surgical excision will have half of the surgical area pre-treated with PDL and the other
half pre-treated with cryogen spray.
Inclusion Criteria:
- Subjects with ages between 18 and 65 years, who are scheduled for a dermatologic
surgical excision
- Subjects requiring surgical excisions for any condition
- Subjects with any Fitzpatrick skin type
- Willingness to participate in the study
- Willingness to receive experimental treatment
- Informed consent agreement signed by the subject
- Willingness to follow the follow-up schedule
- Willingness to not use any other scar treatments during the study period (i.e scar
massage, over-the-counter silicone pads, intralesional steroid of 5-fluorouracil
injections, laser treatments)
Exclusion Criteria:
- Pregnancy
- Prior scar in area to be treated
- Known photoallergy to visible light (i.e polymorphous light eruption)
- Subject is unable to comply with treatment or follow-up visits
- Subject with a history of being on photosensitive medications for the past 3 months
(thiazides [used to treat high blood pressure], tetracyclines, fluoroquinolones
griseofulvin or sulfonamides [used to treat infections], sulfonylureas [used to treat
diabetes], calcium channel blockers [used to treat hypertension], phenothiazines
[used to treat serious emotional problems]).
- Known autoimmune disease (some autoimmune diseases can lead to sensitivity to light,
such as lupus erythematosus)
- Subject is currently enrolled in a clinical study of any other unapproved
investigational drug or device
We found this trial at
1
site
Click here to add this to my saved trials
